Mindray launches BeneVision N1 for uninterrupted monitoring during intra and out-of-hospital patient transport

Food and Healthcare Press Releases Tuesday January 16, 2018 08:15
SHENZHEN, China--16 Jan--PRNewswire/InfoQuest
The revolutionary transport solution extends intelligent monitoring to out-of-hospital transport settings such as ambulances, helicopters, and civic flights.

Mindray, a global medical equipment solution provider, announced the release of BeneVision N1 Patient Monitor. Designed for the varying demands of both intra and out-of-hospital patient transport, BeneVision N1 provides a steadfast and versatile solution that integrates seamlessly into the BeneVision Patient Monitoring Solution with maximum mobility, patient-centric data continuity and streamlined workflow. In compliance with out-of-hospital patient transport standards such as EN1789, EN13718-1, IEC60601-1-12 and U.S. military standards, N1 is a highly competent solution for various out-of-hospital transport settings both on land and in air.

BeneVision N1 combines state-of-the-art design, innovative technology with a clinically tested ease-of-use workflow, all while maintaining patient data continuity. Weighing less than 1kg, the palm-sized monitor provides clear viewing from all angles with HD display touchscreen and streamlined workflow with intuitive operation.

With Platinum Multi-parameter Platform, BeneVision N1's enhanced data analysis greatly improves parameters' accuracy and anti-interference ability. Its fully integrated sidestream CO2 module monitors the patient's breathing situation by connecting with sampling line directly, saving the shackles of expanding external modules for transport.

BeneVision N1 adapts to the clinical needs across the hospital from a plug-and-play module, to transport, to a stand-alone bedside monitor. It can be connected into BeneVision N-Series bedside monitor as a module or function as an independent bedside monitor. The connectivity capabilities of BeneVision N1 enables it to follow a patient throughout the entire care process, ensuring data continuity for patient-centric monitoring, thereby improving overall information management efficiency.

Integrating Mindray's latest monitoring technological innovations to address clinical needs, BeneVision N1 is designed to provide caregivers and hospitals with more value and efficiency. With its release, Mindray is set to continue the pioneering position in patient transport monitoring solutions and proven success of its previous BeneView T1 transport monitor which has been widely acknowledged in the market.

For more information on the full BeneVision Patient Monitoring Solution, visit http://www.mindray.com/en/productlist/High_Acuity_PMS.html
About Mindray:

Mindray is a leading global medical solution provider, dedicated to making better healthcare more accessible to humanity. Since its foundation in 1991, Mindray has been focused on the medical industry in the fields of Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging.

Contact:
Hailey Peng
Mindray Communication Office
hailey.speng@mindray.com
Photo - https://photos.prnasia.com/prnh/20180115/2032243-1

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics